Biointron

👏 Congratulations to China Medical System Holdings Limited for the approval of silevimig, a bispecific antibody for passive immunization against rabies!

China’s NMPA has approved the novel drug silevimig, the world’s first fully human bispecific antibody targeting dual epitopes of the rabies virus. It demonstrates broad neutralization, which can effectively neutralize different viral strains or genotypes of RABV, providing immediate protection.

Silevimig works by targeting the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and III. Through this mechanism, silevimig specifically neutralizes the RABV prior to the establishment of full protection by active rabies vaccination.

Read the press release here 👉 https://www.globenewswire.com/news-release/2026/06/22/3315186/0/en/cms-class-1-innovative-drug-silevimig-injection-approved-in-china-becoming-the-world-s-first-bispecific-antibody-for-passive-immunization-against-rabies.html

CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies SHENZHEN, CHINA, June 22, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS”, or the “Group”) is pleased to announce...

𝗪𝗵𝗮𝘁 𝗶𝗳 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝗰𝗼𝘂𝗹𝗱 𝗯𝗲 𝘁𝘂𝗿𝗻𝗲𝗱 𝗢𝗡 𝗮𝗻𝗱 𝗢𝗙𝗙? 💡

A new study from KAIST researchers introduces “extrabody”, an optogenetic, stimulus-gated antibody platform that brings spatiotemporal control to antigen recognition.

Extrabody is based on split antibody fragments (derived from nanobody or scFv) that remain inactive until triggered. Upon blue light or small-molecule inducers, the fragments reassemble, enabling inducible extracellular antigen recognition.

At Biointron, we’re excited to see how innovations like this push antibody discovery toward more dynamic, data-driven design.

Read the full paper here 👉 https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(26)00141-8

An extracellular, optogenetic antibody platform for stimulus-gated antigen recognition and modulation of cell behavior Precise control of antigen recognition remains a challenge in engineering cell-cell interactions. Kwon et al. develop extrabody, a split antibody platform that enables optogenetic and chemical control of extracellular antigen binding, allowing inducible cell-cell communication and programmable immun...